MedTrace Logo

Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease

NCT01752985 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 319

Last updated 2019-07-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether BMS-813160 will reduce the amount of protein loss in the urine of subjects with type 2 diabetes and diabetic kidney disease

Conditions

  • Diabetic Kidney Disease

Interventions

DRUG

BMS-813160

DRUG

Placebo matching with BMS-813160

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-18
Primary Completion
2015-06-30
Completion
2015-06-30

Countries

  • United States
  • Canada
  • Denmark
  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01752985 on ClinicalTrials.gov